GLP-1

Novo Nordisk has received approval in Singapore for Wegovy as the first treatment for MASH, a liver disease involving fibrosis. It marks a new indication for the weight-loss drug beyond obesity and diabetes. Attention centres on how semaglutide could expand into treating fatty liver disease globally.

New reporting indicates that close to one in six pediatric patients taking GLP-1 medications experience a nutritional deficiency. The finding highlights a potential nutritional risk for children and adolescents using these weight-loss and diabetes drugs, adding to ongoing scrutiny of their growing use in younger populations. Clinicians are being reminded to monitor nutrition in patients on GLP-1 therapy, as reduced appetite and dietary intake may contribute to deficiencies.

ETF Trends is hosting a webcast focused on how investors can gain exposure to the peptide economy, the growing sector built around peptide-based drugs and therapies. The session is expected to cover market opportunities and investment vehicles tied to the biotech and pharmaceutical companies driving demand in this space.

Some patients taking GLP-1 weight-loss drugs such as Ozempic and Wegovy are experimenting with microdosing, using lower doses than prescribed, often to cut costs or reduce side effects. An obesity medicine doctor is explaining what the practice involves and urging caution, since evidence for smaller-than-approved doses is limited and self-adjusting medication without medical supervision carries risks.